Can You ID ADHD? Tips and Tools to Improve Your Rate of Detection in AdultsPremiere Date: Thursday, December 30, 2021
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, December 30, 2022
Note: Credit Is No Longer Available
|Ann Childress, MD (Moderator)
President, Center for Psychiatry and Behavioral Medicine, Inc.
Associate Professor Child/Adolescent Psychiatry
Touro University Nevada College of Osteopathic Medicine
Clinical Associate Professor
University of Nevada, Las Vegas School of Medicine
Las Vegas, NV
|Theresa Cerulli, MD
Beth Israel Deaconess Medical Center
Medical Director, Cerulli and Associates
North Andover, MA
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that varies in its symptom presentation and functional impact across the lifespan. Although it is now recognized that ADHD may persist to adulthood, it often goes undetected in adults, being misdiagnosed as other psychiatric and frequently comorbid conditions. Diagnosis is complicated in that symptom presentation may vary as the individual transitions from childhood to adulthood. The use of diagnostic criteria and evidence-based tools can help to differentiate the diagnosis of ADHD in adults, particularly in the context of comorbidities. This is imperative because an accurate diagnosis not only facilitates early intervention but also offers a sense of relief as difficulties experienced at home and work are now explained.
This CME Outfitters activity will provide clinicians with the appropriate tools to facilitate the early detection of ADHD in adults, particularly within the context of comorbidities.
At the end of this CE activity, participants should be able to:
- Utilize updated diagnostic criteria and screening tools to accurately diagnose ADHD in adults.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Psychiatrists, psychiatric nurses, pediatricians, primary care providers, PAs, nurse practitioners, nurses, and pharmacists
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Childress reports that she receives research support from Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals; KemPharm, Inc.; Neos Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc. She reports that she is on the speakers bureau for Corium Inc.; Ironshore Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc. She reports that she is a consultant for Aardvark Therapeutics, Inc.; Corium Inc.; Jazz Pharmaceuticals, Inc.; KemPharm, Inc.; Lumos Pharma; Neos Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Tulex Pharmaceuticals. She reports that she receives writing support for Purdue Pharma L.P.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Cerulli has no disclosures to report.
S. Michelle Franks, MSN, APRN, FNP-BC (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Susan H. Yarbrough, CHCP (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).